Provided by Tiger Trade Technology Pte. Ltd.

Immuneering Corp

5.02
+0.16003.29%
Post-market: 4.97-0.0500-1.00%16:48 EDT
Volume:7.29M
Turnover:36.44M
Market Cap:324.14M
PE:-3.94
High:5.03
Open:4.81
Low:4.76
Close:4.86
52wk High:10.08
52wk Low:1.10
Shares:64.57M
Float Shares:54.41M
Volume Ratio:5.77
T/O Rate:13.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2729
EPS(LYR):-1.2729
ROE:-43.12%
ROA:-26.07%
PB:1.48
PE(LYR):-3.94

Loading ...

Immuneering: Expects to Share Topline Results From Trial in Mid-2028

THOMSON REUTERS
·
Dec 18, 2025

Immuneering Expects to Dose First Patient in Global Phase 3 Registrational Trial, Mapkeeper 301, in Mid-2026

THOMSON REUTERS
·
Dec 18, 2025

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

GlobeNewswire
·
Dec 18, 2025

Immuneering Corporation joins Nasdaq Biotechnology Index

Reuters
·
Dec 16, 2025

Immuneering Corporation to Present at Piper Sandler Annual Healthcare Conference

Reuters
·
Nov 25, 2025

U.S. RESEARCH ROUNDUP-Alignment Healthcare, BJ's Wholesale Club Holdings, Hyatt Hotels

Reuters
·
Nov 24, 2025

Immuneering Showcases Promising Phase 2 Pancreatic Cancer Data for Atebimetinib Combination

Reuters
·
Nov 22, 2025

Immuneering (IMRX) Gets a Buy from Mizuho Securities

TIPRANKS
·
Nov 18, 2025

Immuneering Corp. Shines in Positive Earnings Call

TIPRANKS
·
Nov 14, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Broadwind, Verizon, APA

Reuters
·
Nov 14, 2025

BUZZ-Immuneering rises after smaller-than-expected Q3 loss

Reuters
·
Nov 13, 2025

Immuneering Is Maintained at Buy by Chardan Capital

Dow Jones
·
Nov 13, 2025

Immuneering reports Q3 EPS (38c), consensus (39c)

TIPRANKS
·
Nov 13, 2025

Immuneering expects cash to fund operations into 2029

TIPRANKS
·
Nov 13, 2025

Immuneering reports smaller-than-expected Q3 net loss

Reuters
·
Nov 13, 2025

Immuneering Granted U.S. Patent for Atebimetinib, Providing Exclusivity Into 2042

Reuters
·
Nov 13, 2025

Immuneering Q3 EPS $(0.38) Beats $(0.39) Estimate

Benzinga
·
Nov 13, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 12, 2025

Immuneering Corporation to Release Third Quarter 2025 Financial Results

Reuters
·
Nov 05, 2025

Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

GlobeNewswire
·
Nov 05, 2025